Ironwood Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2024 | IRWD

Ironwood Pharmaceuticals retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Ironwood Pharmaceuticals Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $-1,699
2022 $-696
2021 $-938
2020 $-1,466
2019 $-1,572
2018 $-1,591
2017 $-1,309
2016 $-1,192
2015 $-1,110
2014 $-967
2013 $-778
2012 $-505
2011 $-432
2010 $-368
2009 $-315
Ironwood Pharmaceuticals Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-09-30 $-1,700
2024-06-30 $-1,704
2024-03-31 $-1,703
2023-12-31 $-1,699
2023-09-30 $-1,698
2023-06-30 $-1,713
2023-03-31 $-651
2022-12-31 $-696
2022-09-30 $-745
2022-06-30 $-796
2022-03-31 $-833
2021-12-31 $-938
2021-09-30 $-979
2021-06-30 $-1,035
2021-03-31 $-1,426
2020-12-31 $-1,466
2020-09-30 $-1,509
2020-06-30 $-1,544
2020-03-31 $-1,569
2019-12-31 $-1,572
2019-09-30 $-1,620
2019-06-30 $-1,641
2019-03-31 $-1,650
2018-12-31 $-1,591
2018-09-30 $-1,576
2018-06-30 $-1,401
2018-03-31 $-1,352
2017-12-31 $-1,309
2017-09-30 $-1,321
2017-06-30 $-1,289
2017-03-31 $-1,244
2016-12-31 $-1,192
2016-09-30 $-1,178
2016-06-30 $-1,145
2016-03-31 $-1,123
2015-12-31 $-1,110
2015-09-30 $-1,096
2015-06-30 $-1,049
2015-03-31 $-1,001
2014-12-31 $-967
2014-09-30 $-930
2014-06-30 $-888
2014-03-31 $-827
2013-12-31 $-778
2013-09-30 $-726
2013-06-30 $-664
2013-03-31 $-599
2012-12-31 $-505
2012-09-30 $-461
2012-06-30 $-509
2012-03-31 $-468
2011-12-31 $-432
2011-09-30 $-425
2011-06-30 $-405
2011-03-31 $-386
2010-12-31 $-368
2010-09-30 $-356
2010-06-30 $-348
2010-03-31 $-330
2009-12-31 $-315
2009-09-30 $-291
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.534B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $79.725B 30.68
Takeda Pharmaceutical (TAK) Japan $42.414B 8.83
Sandoz Group AG (SDZNY) Switzerland $19.283B 0.00
Merck (MKKGY) Germany $18.792B 16.83
Astellas Pharma (ALPMY) Japan $18.332B 16.88
United Therapeutics (UTHR) United States $16.401B 16.13
Summit Therapeutics (SMMT) United States $13.584B 0.00
Neurocrine Biosciences (NBIX) United States $12.656B 33.51
Shionogi (SGIOY) Japan $11.814B 11.32
Catalent (CTLT) United States $10.829B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.563B 7.40
Madrigal Pharmaceuticals (MDGL) United States $7.181B 0.00
Orion OYJ (ORINY) Finland $6.653B 18.71
Corcept Therapeutics (CORT) United States $5.859B 44.38
Ionis Pharmaceuticals (IONS) United States $5.359B 0.00
Crinetics Pharmaceuticals (CRNX) United States $5.289B 0.00
PTC Therapeutics (PTCT) United States $3.308B 0.00
Dyne Therapeutics (DYN) United States $3.026B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.578B 15.41
Catalyst Pharmaceuticals (CPRX) United States $2.519B 11.42
Soleno Therapeutics (SLNO) United States $2.356B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.272B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.061B 0.00
Evotec AG (EVO) Germany $1.896B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.859B 0.00
Xencor (XNCR) United States $1.687B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.648B 0.00
Harrow (HROW) United States $1.563B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.551B 0.00
Cassava Sciences (SAVA) United States $1.548B 0.00
Indivior (INDV) United States $1.484B 6.04
Guardian Pharmacy Services (GRDN) United States $1.397B 0.00
Ocular Therapeutix (OCUL) United States $1.339B 0.00
ARS Pharmaceuticals (SPRY) United States $1.300B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.256B 0.00
Enliven Therapeutics (ELVN) United States $1.242B 0.00
Ardelyx (ARDX) United States $1.213B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.124B 0.00
Collegium Pharmaceutical (COLL) United States $0.981B 5.35
Bioventus (BVS) United States $0.934B 29.51
Cronos Group (CRON) Canada $0.784B 0.00
Relay Therapeutics (RLAY) United States $0.777B 0.00
USANA Health Sciences (USNA) United States $0.750B 13.91
Oruka Therapeutics (ORKA) United States $0.717B 0.00
Elite Pharmaceuticals (ELTP) United States $0.660B 0.00
Exscientia (EXAI) United Kingdom $0.633B 0.00
Altimmune (ALT) United States $0.598B 0.00
Tourmaline Bio (TRML) United States $0.583B 0.00
Savara (SVRA) United States $0.556B 0.00
OmniAb (OABI) United States $0.544B 0.00
Organogenesis (ORGO) United States $0.533B 0.00
ProKidney (PROK) United States $0.507B 0.00
Zevra Therapeutics (ZVRA) United States $0.487B 0.00
Esperion Therapeutics (ESPR) United States $0.487B 0.00
Korro Bio (KRRO) United States $0.474B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.473B 0.00
Xeris Biopharma Holdings (XERS) United States $0.453B 0.00
Siga Technologies (SIGA) United States $0.448B 5.22
Rigel Pharmaceuticals (RIGL) United States $0.441B 178.86
Aquestive Therapeutics (AQST) United States $0.411B 0.00
KalVista Pharmaceuticals (KALV) United States $0.403B 0.00
Akebia Therapeutics (AKBA) United States $0.397B 0.00
Larimar Therapeutics (LRMR) United States $0.391B 0.00
Verve Therapeutics (VERV) United States $0.389B 0.00
4D Molecular Therapeutics (FDMT) United States $0.369B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.356B 0.00
Avita Medical (RCEL) United States $0.337B 0.00
Aclaris Therapeutics (ACRS) United States $0.309B 0.00
Sage Therapeutics (SAGE) United States $0.297B 0.00
Nature's Sunshine Products (NATR) United States $0.289B 17.21
Aldeyra Therapeutics (ALDX) United States $0.286B 0.00
Lyell Immunopharma (LYEL) United States $0.256B 0.00
Silence Therapeutics (SLN) United Kingdom $0.230B 0.00
Lexeo Therapeutics (LXEO) United States $0.205B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.204B 0.00
Acrivon Therapeutics (ACRV) United States $0.201B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.197B 0.00
Nektar Therapeutics (NKTR) United States $0.186B 0.00
Profound Medical (PROF) Canada $0.185B 0.00
MediWound (MDWD) Israel $0.181B 0.00
Nanobiotix S.A (NBTX) France $0.181B 0.00
Galectin Therapeutics (GALT) United States $0.171B 0.00
Heron Therapeutics (HRTX) United States $0.161B 0.00
Achieve Life Sciences (ACHV) Canada $0.149B 0.00
CytoDyn (CYDY) United States $0.144B 0.00
VAXART, INC (VXRT) United States $0.136B 0.00
Inhibikase Therapeutics (IKT) United States $0.135B 0.00
Telomir Pharmaceuticals (TELO) United States $0.132B 0.00
Cardiol Therapeutics (CRDL) Canada $0.129B 0.00
Pyxis Oncology (PYXS) United States $0.125B 0.00
Context Therapeutics (CNTX) United States $0.113B 0.00
Journey Medical (DERM) United States $0.109B 0.00
Century Therapeutics (IPSC) United States $0.105B 0.00
Innate Pharma SA (IPHYF) France $0.103B 0.00
Avalo Therapeutics (AVTX) United States $0.100B 0.00
Fractyl Health (GUTS) United States $0.099B 0.00
Karyopharm Therapeutics (KPTI) United States $0.097B 0.00
Assertio Holdings (ASRT) United States $0.092B 24.14
Regulus Therapeutics (RGLS) United States $0.092B 0.00
Arch Biopartners (ACHFF) Canada $0.090B 0.00
Inotiv (NOTV) United States $0.089B 0.00
PMV Pharmaceuticals (PMVP) United States $0.083B 0.00
Relmada Therapeutics (RLMD) United States $0.083B 0.00
CASI Pharmaceuticals (CASI) China $0.081B 0.00
Vivani Medical (VANI) United States $0.079B 0.00
ESSA Pharma (EPIX) Canada $0.078B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 0.00
Scienture Holdings (SCNX) United States $0.069B 0.00
Metagenomi (MGX) United States $0.068B 0.00
AlloVir (ALVR) United States $0.066B 0.00
ElectroCore (ECOR) United States $0.065B 0.00
OptiNose (OPTN) United States $0.060B 0.00
Champions Oncology (CSBR) United States $0.058B 0.00
Mural Oncology (MURA) Ireland $0.057B 0.00
BioVie (BIVI) United States $0.055B 0.00
Nutriband (NTRB) United States $0.055B 0.00
Unicycive Therapeutics (UNCY) United States $0.055B 0.00
Prelude Therapeutics (PRLD) United States $0.053B 0.00
Rafael Holdings (RFL) United States $0.050B 0.00
Iterum Therapeutics (ITRM) Ireland $0.049B 0.00
Protara Therapeutics (TARA) United States $0.047B 0.00
SCYNEXIS (SCYX) United States $0.045B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.045B 0.00
Gain Therapeutics (GANX) United States $0.043B 0.00
VYNE Therapeutics (VYNE) United States $0.043B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.041B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Tempest Therapeutics (TPST) United States $0.039B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.038B 0.00
CERo Therapeutics Holdings (CERO) United States $0.037B 0.00
Carisma Therapeutics (CARM) United States $0.035B 0.00
Incannex Healthcare (IXHL) Australia $0.035B 0.00
Surrozen (SRZN) United States $0.030B 0.00
Citius Pharmaceuticals (CTXR) United States $0.030B 0.00
DURECT (DRRX) United States $0.027B 0.00
Lipocine (LPCN) United States $0.027B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.026B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
BioLineRx (BLRX) Israel $0.026B 0.00
GlycoMimetics (GLYC) United States $0.021B 0.00
MEI Pharma (MEIP) United States $0.019B 0.00
ProPhase Labs (PRPH) United States $0.019B 0.00
Enlivex Therapeutics (ENLV) Israel $0.018B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.018B 0.00
Cosmos Health (COSM) United States $0.018B 0.00
PolyPid (PYPD) Israel $0.016B 0.00
Mannatech (MTEX) United States $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.015B 0.00
TherapeuticsMD (TXMD) United States $0.015B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.015B 0.00
NRx Pharmaceuticals (NRXP) United States $0.015B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Traws Pharma (TRAW) United States $0.014B 0.00
Nuvilex (PMCB) United States $0.013B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.013B 0.00
Lyra Therapeutics (LYRA) United States $0.012B 0.00
Talphera (TLPH) United States $0.012B 0.00
Jaguar Animal Health (JAGX) United States $0.012B 0.00
Conduit Pharmaceuticals (CDT) United States $0.011B 0.00
Indaptus Therapeutics (INDP) United States $0.011B 0.00
Dominari Holdings (DOMH) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Redhill Biopharma (RDHL) Israel $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Klotho Neurosciences (KLTO) United States $0.008B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
TransCode Therapeutics (RNAZ) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Ainos (AIMD) United States $0.006B 0.00
Viracta Therapeutics (VIRX) United States $0.006B 0.00
Biomerica (BMRA) United States $0.005B 0.00
Aditxt (ADTX) United States $0.005B 0.00
SHINECO (SISI) China $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.11
Aptorum Group (APM) United Kingdom $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Bio-Path Holdings (BPTH) United States $0.003B 0.00
Oncternal Therapeutics (ONCT) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Molecular Templates (MTEM) United States $0.003B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
PainReform (PRFX) Israel $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 2.13
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 38.47